lacosamide · Ucb Inc · NDA 022253, 022254, 022255
Vimpat
Earliest generic entry, as listed · earliest of 6 marketed strengths
Open now
No unexpired patents or exclusivities are listed for this product.
Listed patents · 0 unexpired
No unexpired patents listed.
Exclusivities · 0 unexpired
No unexpired exclusivities listed.
Paragraph IV certifications · 0
No Paragraph IV certification listed by FDA for this drug.
The list shows that a generic applicant certified to FDA that a listed patent is invalid or not infringed. It does not show litigation, settlements or launch timing.
Event history
- Generic approved · ANDA 217596, Prod Development · 022255-001Approved 15 Jun 2026Detected 25 Oct 2026Historical import
- Generic approved · ANDA 220386, Regcon Holdings · 022255-001Approved 29 Jan 2026Detected 25 Oct 2026Historical import
- Generic approved · ANDA 220366, Adaptis · 022255-001Approved 21 May 2026Detected 25 Oct 2026Historical import
- Generic approved · ANDA 220268, Glenmark Pharms · 022254-001Approved 21 Jan 2026Detected 25 Oct 2026Historical import
Products covered · 6
| NDA · product | Form | Strength | Listed expiry |
|---|---|---|---|
| 022253 · 001 · RLD | tablet, oral | 50MG | open |
| 022253 · 002 · RLD | tablet, oral | 100MG | open |
| 022253 · 003 · RLD | tablet, oral | 150MG | open |
| 022253 · 004 · RLD | tablet, oral | 200MG | open |
| 022254 · 001 · RLD | solution, intravenous | 200MG/20ML (10MG/ML) | open |
| 022255 · 001 · RLD | solution, oral | 10MG/ML | open |
Expired or delisted (1)
- D-188 · 28 Apr 2026